Medtronic Starts US DES Trial for Small Vessel CAD Patients - Analyst Blog

Medical technology giant Medtronic plcMDT recently initiated the Resolute Onyx Clinical Program in the U.S. This study aims at estimating the clinical efficacy of the company's Resolute Onyx drug eluting stent (DES) in patients who suffer from coronary artery disease.

The study is in line with Medtronic's attempts to offer advanced solutions for unmet medical needs in cardiovascular diseases facilitated by the joint efforts of improved biologics and therapy delivery devices.

In its initial phase, this study will consider patients who have small blood vessels and hence require a 2.0 mm sized stent. Notably, before this trial, most patients with narrow blood vessels were considered untreatable with a DES.

According to Medtronic's management, one of the toughest challenges that a healthcare provider in the interventional cardiology market face is that of treating coronary artery disease (CAD) patients with small blood vessels. Unfortunately, such a medical condition is rather common in diabetic patients who suffer from heart ailments, and this patient population is rapidly increasing every year across the globe.

Medtronic's Resolute Onyx DES - a next-generation coronary stent that has been developed on the proven clinical performance and superior deliverability of Medtronic's well-acclaimed Resolute Integrity DES - incorporates the CoreWire Technology, which offers advanced visibility during the stenting procedure.

The device also helps in providing improved deliverability without compromising radial and longitudinal strength. This enhances the efficiency of stent implanting (stenting) procedures.

Currently, the Resolute Onyx DES is not available for commercial purposes in the U.S. However, it is available in the European countries that approve the CE Mark, which the device received in Nov 2014. The company is currently seeing healthy uptake of this device in these countries.

With the Resolute Onyx Clinical Program off to a start, management expects to highlight the technological advancements that allow Resolute Onyx DES to enable physicians to increase procedural efficiency and enhanced deliverability in stenting procedures, involving a wide range of vessel sizes.

In the last reported fiscal third quarter, with respect to its broader Coronary product portfolio, the company has been experiencing the continued rollout of its new NC Euphora Noncompliant PTCA Balloon family, as well as strong sequential growth in U.S. revenues from its FFR co-promotion alliance with Acist Medical Systems.

In Feb 2015, Medtronic launched the Euphora Semicompliant Balloon Dilatation Catheter in countries that recognize the CE mark. It is not yet commercially available in the U.S.

We believe such back-to-back achievements in the global coronary market will allow Medtronic to expand its share in there, going forward. In particular, we expect the domestic coronary market to ride high on the back of the Resolute Onyx DES, once it becomes available in the U.S.

Currently, the stock carries a Zacks Rank #2 (Buy). Some other top-ranked medical products stocks are Abaxis, Inc. ABAX , LeMaitre Vascular, Inc. LMAT and Phibro Animal Health Corp. PAHC . All three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDTRONIC (MDT): Free Stock Analysis Report

ABAXIS INC (ABAX): Free Stock Analysis Report

LEMAITRE VASCLR (LMAT): Free Stock Analysis Report

PHIBRO ANIMAL (PAHC): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics